Balancer is proposing to shut down its decentralized exchange protocol and return over $9 million in remaining treasury assets to BAL token holders. This decision follows a major exploit in November 2025 that caused a $128 million loss and a steep decline in revenue, which fell from $1.13 million in October 2025 to just $56,781 in August 2026. The protocol's attempt to recover revenue with a leaner operating model failed, leading to the planned phased shutdown starting in October 2026. BAL holders will vote on the proposal from September 25 to 29, with liquidity providers given until October 30 to exit before the protocol moves to withdrawal-only mode in November. The remaining treasury funds will be distributed to BAL holders in stages, requiring token burns for claims.
Balancer's proposed shutdown follows a major exploit and revenue decline. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Sep 15, 2026 10:21 WIB: out of 50 major cryptocurrencies, 23 rose and 26 fell. Notable movers include GRT at Rp319 with a -4.70% change, VET at Rp134 with a -4.19% change, and ZIL at Rp54 with a +4.08% change.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
